Vaxart's (NASDAQ:VXRT) shares rose following the positive results from an early-stage trial of its new oral pill vaccine for norovirus, a more advanced version compared to its first-generation ...

Vaxart CEO Steven Lo stated that the company believes its second-generation norovirus oral pill vaccine candidate "has the potential to provide first-in-class or best-in-class protection" against ...

Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025.

While the outlook for vaccines in the US looks bleak under Trump's administration, the UK is pressing ahead with securing its ...

With no currently approved vaccine, norovirus causes millions of infections globally resulting in billions of dollars of economic burden,” said Steven Lo, Chief Executive Officer of Vaxart.

The company continues to focus on its oral recombinant vaccine platform, developing candidates for diseases such as coronavirus, norovirus, influenza, and HPV. 3rd party Ad.

Before the early 2000s, when a rotavirus vaccine began to be widely used in the US, it’s estimated that about 60,000 American children were hospitalized every year with the disease.

The health and human services secretary has repeatedly claimed children need dozens more vaccines than they actually do.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.